By SPC News Staff
The FDA today approved inotuzumab ozogamicin (Besponsa, Pfizer) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. The National Cancer Institute estimates that approximately 5,970 people in the United States will be diagnosed with ALL this year, and approximately